Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxcarbazepine for Chronic Peripheral Neuropathic Pain
NCT01302275Phase 4
Key facts
- Status
- Completed
- Start
- Feb 2011
- Primary completion
- May 2013
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- oxcarbazepine
- Conditions
- Peripheral neuropathic pain
01
Overview
Phase 4, randomised, double-blind trial of oxcarbazepine in Peripheral neuropathic pain. Primary endpoint: Total pain rated on numeric rating scale at 6 weeks. Started Feb 2011; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Adults with chronic peripheral neuropathic pain (NRS >= 4) due to polyneuropathy, nerve injury, or postherpetic neuralgia, excluding those with renal/hepatic impairment, epilepsy, or psychiatric disorders.
04
Endpoints
Primary
Total pain rated on numeric rating scale
Secondary
Response defined as at least 50% reduction in pain score
Beyond the preview
Go deeper on NCT01302275.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01302275.